Aktienanalyse zu Apollomics Inc (APLM)APLMApollomics Inc

Apollomics Inc. is a clinical-stage biopharmaceutical company focusing on discovering and developing oncology therapies to address unmet medical needs, especially for difficult-to-treat and treatment-resistant cancers. The product candidates in its pipeline are categorized into two groups based on their mechanisms of action, each of which contains product candidates at different stages of development: tumor inhibitors and immuno-oncology drugs. Its tumor inhibitor product candidates consist of three small-molecule inhibitors against different uncontrolled growth signaling pathways in cancer cells: vebreltinib, APL-102 and APL-122. Its three immuno-oncology product candidates consist of APL-501, APL-502 and APL-80. Vebreltinib is a potent, oral active selective c-Met inhibitor. APL-102 is an oral active, small molecule Multiple Tyrosine Kinase Inhibitor. APL-122 is a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways. APL-501 is an anti-PD-1 antibody product candidate. It operates in the Financials sector (PHARMACEUTICAL PREPARATIONS industry).

Apollomics Inc. (APLM) appears to be a good buy right now due to its recent 5-day price increase of 4.72%, indicating positive momentum, and the fact that it is currently trading at $20.84, which is 56.2% of its 52-week range, suggesting potential for further upside. Additionally, the company has secured $10 million in private placement funding, demonstrating strong confidence from management and investors. However, the main risk is its negative earnings, with a forward P/E of 0 and a net income loss of $9,326,000 in Q1 2025, which indicates ongoing financial challenges that investors should monitor closely.